The cure STARTs here.

START is dedicated to the conduct of Phase I Clinical Trials of novel
anticancer agents.

The mission of START is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START operates under the leadership of Dr. Anthony W. Tolcher, Dr. Amita Patnaik and Dr. Kyriakos P. Papadopoulos and consists of a team of highly trained staff with extensive experience in Phase I clinical trials research.

Clinical Research

New Hope for Patients. . . New Hope for a Cure

With centers located in San Antonio, Texas and Madrid, Spain, START conducts the world’s largest Phase I medical oncology program. Today, more than 50 percent of cancer patients can be cured with conventional treatments – that is, therapies with a proven response rate. However, there are many patients who do not respond to standard treatment and may be eligible for participation in our Phase I clinical trials program.

Preclinical Research

START is dedicated to developing improved preclinical models and assays to accelerate oncology drug development.

START's preclinical program is unique in that our researchers work alongside leading Phase I clinicians whose clinical experience and collaboration allows us to accelerate the movement of agents through preclinical development and into first in man studies.